| Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) (NCT05093972) | Merck Sharp & Dohme LLC | 2027-01-22 |
| A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) (NCT07700758) | Merck Sharp & Dohme LLC | 2026-11-23 |
| A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) (NCT07600723) | Merck Sharp & Dohme LLC | 2026-11-04 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) (NCT07705607) | Merck Sharp & Dohme LLC | 2026-09-30 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) (NCT07722611) | Merck Sharp & Dohme LLC | 2026-09-21 |
| A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008) (NCT07743151) | Merck Sharp & Dohme LLC | 2026-09-15 |
| A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) (NCT07600775) | Merck Sharp & Dohme LLC | 2026-09-01 |
| A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) (NCT07646860) | Merck Sharp & Dohme LLC | 2026-08-31 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) (NCT07705555) | Merck Sharp & Dohme LLC | 2026-08-28 |
| A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007) (NCT07748351) | Merck Sharp & Dohme LLC | 2026-08-25 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) (NCT07709000) | Merck Sharp & Dohme LLC | 2026-08-21 |
| A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) (NCT07734610) | Merck Sharp & Dohme LLC | 2026-08-17 |
| A Study of V132 in Healthy Older Participants (V132-001) (NCT07712575) | Merck Sharp & Dohme LLC | 2026-08-17 |
| A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) (NCT07595263) | Merck Sharp & Dohme LLC | 2026-08-17 |
| A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007) (NCT07677163) | Merck Sharp & Dohme LLC | 2026-07-29 |
| A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005) (NCT07697625) | Merck Sharp & Dohme LLC | 2026-07-20 |
| A Clinical Study of V540A in Healthy Female Participants (V540A-005) (NCT07224477) | Merck Sharp & Dohme LLC | 2026-07-20 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) (NCT07743164) | Merck Sharp & Dohme LLC | 2026-07-17 |
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) (NCT07630974) | Merck Sharp & Dohme LLC | 2026-07-02 |
| A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003) (NCT07619443) | Merck Sharp & Dohme LLC | 2026-07-01 |
| A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) (NCT07614984) | Merck Sharp & Dohme LLC | 2026-06-30 |
| A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) (NCT07661108) | Merck Sharp & Dohme LLC | 2026-06-30 |
| A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) (NCT07302347) | Merck Sharp & Dohme LLC | 2026-06-23 |
| A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) (NCT07554339) | Merck Sharp & Dohme LLC | 2026-06-18 |
| Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) (NCT07600749) | Merck Sharp & Dohme LLC | 2026-06-18 |
| A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020) (NCT07528508) | Merck Sharp & Dohme LLC | 2026-05-22 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) (NCT07570173) | Merck Sharp & Dohme LLC | 2026-05-18 |
| A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (NCT07548606) | Merck Sharp & Dohme LLC | 2026-05-11 |
| A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) (NCT07513376) | Merck Sharp & Dohme LLC | 2026-05-04 |
| A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) (NCT07519772) | Merck Sharp & Dohme LLC | 2026-05-03 |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (NCT07286149) | Merck Sharp & Dohme LLC | 2026-04-30 |
| A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) (NCT07530289) | Merck Sharp & Dohme LLC | 2026-04-29 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) (NCT07419295) | Merck Sharp & Dohme LLC | 2026-04-23 |
| Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) (NCT07486960) | Merck Sharp & Dohme LLC | 2026-04-20 |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) (NCT07489495) | Merck Sharp & Dohme LLC | 2026-04-09 |
| A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) (NCT07199465) | Merck Sharp & Dohme LLC | 2026-03-30 |
| A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) (NCT07405151) | Merck Sharp & Dohme LLC | 2026-03-27 |
| A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) (NCT07463183) | Merck Sharp & Dohme LLC | 2026-03-24 |
| Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) (NCT07405164) | Merck Sharp & Dohme LLC | 2026-03-23 |
| A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) (NCT07431866) | Merck Sharp & Dohme LLC | 2026-03-18 |
| MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) (NCT07431827) | Merck Sharp & Dohme LLC | 2026-03-18 |
| A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007) (NCT07435194) | Merck Sharp & Dohme LLC | 2026-03-06 |
| A Study of MK-7240 in Healthy Participants (MK-7240-009) (NCT07405177) | Merck Sharp & Dohme LLC | 2026-03-05 |
| A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002) (NCT07388667) | Merck Sharp & Dohme LLC | 2026-03-04 |
| A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) (NCT07363590) | Merck Sharp & Dohme LLC | 2026-02-19 |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (NCT07318558) | Merck Sharp & Dohme LLC | 2026-02-16 |
| KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) (NCT07232602) | Merck Sharp & Dohme LLC | 2026-02-09 |
| A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011) (NCT07334860) | Merck Sharp & Dohme LLC | 2026-02-06 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (NCT07227597) | Merck Sharp & Dohme LLC | 2026-01-29 |
| A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) (NCT07305831) | Merck Sharp & Dohme LLC | 2026-01-22 |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (NCT07216703) | Merck Sharp & Dohme LLC | 2026-01-19 |
| A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (NCT07300267) | Merck Sharp & Dohme LLC | 2026-01-13 |
| A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) (NCT07300280) | Merck Sharp & Dohme LLC | 2025-12-29 |
| A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) (NCT07242469) | Merck Sharp & Dohme LLC | 2025-12-22 |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (NCT07252739) | Merck Sharp & Dohme LLC | 2025-12-19 |
| A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010) (NCT07266818) | Merck Sharp & Dohme LLC | 2025-12-18 |
| A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (NCT07266831) | Merck Sharp & Dohme LLC | 2025-12-18 |
| A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) (NCT07247110) | Merck Sharp & Dohme LLC | 2025-12-16 |
| A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (NCT07221474) | Merck Sharp & Dohme LLC | 2025-12-12 |
| A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) (NCT07222488) | Merck Sharp & Dohme LLC | 2025-12-09 |
| A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) (NCT07232589) | Merck Sharp & Dohme LLC | 2025-12-08 |
| A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) (NCT07209111) | Merck Sharp & Dohme LLC | 2025-12-04 |
| A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) (NCT07227402) | Merck Sharp & Dohme LLC | 2025-11-26 |
| A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016) (NCT07222098) | Merck Sharp & Dohme LLC | 2025-11-19 |
| A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (NCT07216482) | Merck Sharp & Dohme LLC | 2025-11-11 |
| A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (NCT07071623) | Merck Sharp & Dohme LLC | 2025-11-10 |
| A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017) (NCT07219550) | Merck Sharp & Dohme LLC | 2025-11-05 |
| A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004) (NCT07199452) | Merck Sharp & Dohme LLC | 2025-10-28 |
| A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) (NCT06655883) | Merck Sharp & Dohme LLC | 2025-10-09 |
| A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) (NCT07190248) | Merck Sharp & Dohme LLC | 2025-10-08 |
| A Study of V118E in Healthy Participants (V118E-003) (NCT07168915) | Merck Sharp & Dohme LLC | 2025-10-08 |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) (NCT07176390) | Merck Sharp & Dohme LLC | 2025-10-08 |
| A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061) (NCT07086079) | Merck Sharp & Dohme LLC | 2025-09-26 |
| Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) (NCT07089784) | Merck Sharp & Dohme LLC | 2025-09-22 |
| A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015) (NCT07025551) | Merck Sharp & Dohme LLC | 2025-09-19 |
| A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006) (NCT07334886) | Merck Sharp & Dohme LLC | 2025-09-17 |
| A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) (NCT07058077) | Merck Sharp & Dohme LLC | 2025-08-21 |
| A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) (NCT07049939) | Merck Sharp & Dohme LLC | 2025-08-20 |
| A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039) (NCT07121959) | Merck Sharp & Dohme LLC | 2025-08-18 |
| A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014) (NCT07063238) | Merck Sharp & Dohme LLC | 2025-08-12 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (NCT06979596) | Merck Sharp & Dohme LLC | 2025-08-11 |
| A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (NCT07044297) | Merck Sharp & Dohme LLC | 2025-07-31 |
| Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (NCT06780111) | Merck Sharp & Dohme LLC | 2025-07-30 |
| A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) (NCT07030712) | Merck Sharp & Dohme LLC | 2025-07-23 |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (NCT07060807) | Merck Sharp & Dohme LLC | 2025-07-21 |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) (NCT07049926) | Merck Sharp & Dohme LLC | 2025-07-20 |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (NCT06997497) | Merck Sharp & Dohme LLC | 2025-07-16 |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) (NCT07033494) | Merck Sharp & Dohme LLC | 2025-07-16 |
| MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (NCT07042945) | Merck Sharp & Dohme LLC | 2025-07-09 |
| A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040) (NCT07044479) | Merck Sharp & Dohme LLC | 2025-07-03 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (NCT06863272) | Merck Sharp & Dohme LLC | 2025-07-03 |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (NCT06966700) | Merck Sharp & Dohme LLC | 2025-06-30 |
| A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1) (NCT07013487) | Merck Sharp & Dohme LLC | 2025-06-11 |
| Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) (NCT06956235) | Merck Sharp & Dohme LLC | 2025-06-09 |
| A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) (NCT06961006) | Merck Sharp & Dohme LLC | 2025-05-29 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) (NCT06780098) | Merck Sharp & Dohme LLC | 2025-05-28 |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (NCT06952504) | Merck Sharp & Dohme LLC | 2025-05-22 |
| A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) (NCT06780085) | Merck Sharp & Dohme LLC | 2025-05-13 |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (NCT06925737) | Merck Sharp & Dohme LLC | 2025-05-13 |
| A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) (NCT06860243) | Merck Sharp & Dohme LLC | 2025-05-13 |